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AbstrAct
Objectives The objective was to prospectively examine 
potential differences in the risk of first cardiovascular 
disease (CVD) events between South Asians and 
Europeans living in Norway and New Zealand, and to 
investigate whether traditional risk factors could explain 
any differences.
Methods We included participants (30–74 years) without 
prior CVD in a Norwegian (n=16 606) and a New Zealand 
(n=129 449) cohort. Ethnicity and cardiovascular risk 
factor information was linked with hospital registry data 
and cause of death registries to identify subsequent CVD 
events. We used Cox proportional hazards regression 
to investigate the relationship between risk factors and 
subsequent CVD for South Asians and Europeans, and to 
calculate age-adjusted HRs for CVD in South Asians versus 
Europeans in the two cohorts separately. We sequentially 
added the major CVD risk factors (blood pressure, lipids, 
diabetes and smoking) to study their explanatory role in 
observed ethnic CVD risk differences.
results South Asians had higher total cholesterol (TC)/
high-density lipoprotein (HDL) ratio and more diabetes at 
baseline than Europeans, but lower blood pressure and 
smoking levels. South Asians had increased age-adjusted 
risk of CVD compared with Europeans (87%–92% higher 
in the Norwegian cohort and 42%–75% higher in the New 
Zealand cohort) and remained with significantly increased 
risk after adjusting for all major CVD risk factors. Adjusted 
HRs for South Asians versus Europeans in the Norwegian 
cohort were 1.57 (95% CI 1.19 to 2.07) in men and 1.76 
(95% CI 1.09 to 2.82) in women. Corresponding figures for 
the New Zealand cohort were 1.64 (95% CI 1.43 to 1.88) 
in men and 1.39 (95% CI 1.11 to 1.73) in women.
conclusion Differences in TC/HDL ratio and diabetes 
appear to explain some of the excess risk of CVD in 
South Asians compared with Europeans. Preventing 
dyslipidaemia and diabetes in South Asians may therefore 
help reduce their excess risk of CVD.
IntrOductIOn 
Immigrants from South Asia (countries in the 
Indian subcontinent, such as India, Pakistan, 
Sri Lanka and Bangladesh) who have settled 
in Western countries have increased risk of 
cardiovascular disease (CVD) compared with 
their host populations of European origin.1 
This excess risk has been documented in 
several countries, especially the increased 
risk of coronary heart disease (CHD).2–4 We 
recently found that South Asian immigrants 
in Norway had more than twofold higher risk 
of acute myocardial infarction (AMI) than 
ethnic Norwegians and an increased risk of 
stroke (26% higher in men and 58% higher 
in women).5 Collaborators in New Zealand 
found a higher risk of CVD in Indians 
compared with the European New Zealand 
population.6
The mechanisms underlying the increased 
risk of CVD in South Asian populations are 
to a great extent unknown.1 Few studies 
have examined the prospective relationship 
between CVD risk factors and subsequent 
CVD among South Asians,4 7–9 despite the 
urgent need for such studies being addressed 
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strengths and limitations of this study
 ► This is one of few prospective investigations of 
cardiovascular disease and its risk factors in South 
Asian populations living in Western countries.
 ► A special feature is the inclusion of prospective data 
from two different countries enhancing the external 
validity of the findings.
 ► The two cohorts differed in how participants were 
recruited and how information about risk factor 
levels was collected at baseline.
 ► A limited number of South Asians in the Norwegian 
cohort and short follow-up time in the New Zealand 
cohort restricted the statistical power in our 
analyses.
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for more than 10 years ago.10 The two large and multina-
tional case–control studies, INTERHEART11 and INTER-
STROKE,12 indicate that different populations share the 
same risk factors and that the relationship between risk 
factors and CVD is similar in different populations around 
the world. The INTERHEART study also concluded that 
the earlier age of AMI in South Asians can be largely 
attributed to higher risk-factor levels at younger ages.13 
However, the INTERHEART and INTERSTROKE studies 
are both case–control studies. In both Norway and New 
Zealand, South Asians have been found to have similar or 
higher mean total cholesterol (TC) to high-density lipo-
protein (HDL) ratio and higher prevalence of diabetes 
compared with the European majority populations.14–17 
However, they also have lower levels of smoking (espe-
cially women) and mean systolic blood pressure (SBP) 
than the European majority populations. Whether the 
higher risk of CVD among South Asians in Norway and 
New Zealand is due to higher levels of certain risk factors 
have not previously been studied.
Due to the dearth of prospective data on the relation-
ship between risk factors and CVD among South Asians, 
we aimed to prospectively examine possible differences 
in the risk of a first CVD event between South Asians 
and Europeans using cohort studies from Norway and 
New Zealand, and to examine whether traditional CVD 
risk factors could explain such differences. Since the 
two cohorts differ in several aspects we do not intend to 
compare the two cohorts directly, but mainly focus on 
within-country comparisons.
MAterIAl And MethOds
the new Zealand PredIct-cVd cohort
We used data from the PREDICT-CVD cohort, collected 
through use of the PREDICT web-based decision support 
program in New Zealand for the assessment and manage-
ment of CVD risk during primary healthcare consul-
tations.18 The study methods and data definitions are 
described in detail elsewhere.18 19 In short, the software 
has been integrated with commonly used primary care 
management systems, and allows systematically coded 
CVD risk data to be automatically and anonymously 
extracted from patients’ electronic medical records and 
augmented where required by primary care staff.18 19 
The cardiovascular profile data was subsequently linked, 
using an encrypted national health identifier number 
to national and regional health datasets with informa-
tion about hospitalisations, deaths, publicly funded drug 
dispensing and laboratory test claims and results.19
The PREDICT software is used in around 35% of New 
Zealand primary care practices mainly in the Auckland 
and Northland regions,19 which serve around 1.7 million 
people, representing around 37% of the New Zealand 
population.20 Any patient with their CVD risk assessed by 
a general practitioner (GP) or practice nurse into online 
PREDICT-CVD forms are included in the PREDICT 
cohort.
New Zealand CVD risk management guidelines recom-
mend that all men aged over 45 years and all women 
aged over 55 years have a regular CVD risk assessment.21 
Specified high-CVD risk groups, including those of South 
Asian ethnicity, are recommended to undergo a risk 
assessment 10 years earlier than the general population.
We used PREDICT data from August 2002 to September 
2012. Members of the cohort were enrolled and exam-
ined continuously throughout this period via their 
contact with the primary healthcare. We included individ-
uals aged 30–74 years since the dataset comprised people 
undergoing a risk assessment based on a Framingham 
risk score intended for people in this age group.22 Using 
information from the GP, hospital discharges and medi-
cation dispensing, we excluded persons with a history of 
CVD (CHD (including angina), stroke, transient isch-
aemic attack (TIA), peripheral vascular disease, percu-
taneous coronary intervention or coronary artery bypass 
grafting), or atrial fibrillation at baseline (n=24 537), and 
people with overt renal disease, those who had estimated 
glomerular filtration rate ≤29 and those with prior hospi-
talisations for congestive heart failure (HF) or who were 
on loop diuretics at baseline (n=1582). Only subjects 
with European or Indian background were included. 
The risk factor measurements in the PREDICT cohort 
were extracted from a standardised electronic template 
that primary care practitioners completed. The SBP was 
based on the mean of the last two recordings done by 
the GP or practice nurse, in most cases with a manual 
mercury sphygmomanometer. Blood lipid and glucose 
or glycated haemoglobin measurements were carried out 
in the community laboratories routinely used by GPs and 
smoking status and other risk factor data were measured 
using a standard questionnaire completed by a primary 
care practitioner.
cohort of norway
We included participants from three surveys conducted 
during 2000 to 2002 in Oslo, Norway; The Oslo Health 
Study (HUBRO), The Oslo Immigrant Health Study 
(I-HUBRO) and The Romsås in Motion study (MoRo 
II) (n=26 709), which are part of the Cohort of Norway 
(CONOR)23; a collection of health data and blood 
samples from several Norwegian health surveys. Partici-
pation rates for the three studies were 40%–46%.23
All CONOR surveys followed the same standard 
procedure for collection of data from self-adminis-
tered questionnaires, physical measurements and blood 
samples. The CONOR questionnaire provided informa-
tion on self-reported diabetes, smoking, use of blood 
pressure (BP) and/or lipid-lowering medication and 
family history of CVD. All participants attended a clin-
ical examination and non-fasting venous blood samples 
were drawn. SBP was measured by an automatic device 
(DINAMAP, Criticon, Tampa, FL, USA) after 2 min of 
seated resting. Three recordings were made at 1-min 
intervals. For the analyses we used the average of the 
second and third SBP measurements. The blood 
 3Rabanal KS, et al. BMJ Open 2017;7:e016819. doi:10.1136/bmjopen-2017-016819
Open Access
samples were subsequently measured for TC and HDL 
cholesterol.23
Using an 11-digit personal identifier, CONOR data were 
linked to hospitalisations and deaths in the Cardiovascular 
Disease in Norway (CVDNOR) project, 1994 to 2009.24 25 
This enabled us to follow CONOR participants for CVD 
outcomes (hospitalisations or deaths) occurring after 
CONOR examination through 31 December 2009.
We included participants aged 30–74 years at base-
line (n=3871 excluded) to ensure comparable samples 
between the Norwegian and New Zealand data. We 
excluded participants not born in Norway or South 
Asia (n=5651 excluded), pregnant women (n=197), 
and participants with prior CVD (CHD, cerebrovascular 
disease, atherosclerotic disease, TIA and HF) (n=353) or 
atrial fibrillation (n=31) registered in the hospital data 
before screening.
Outcomes
In both cohorts, we identified the first CVD event 
(non-fatal and fatal) using main or secondary diagnoses 
from hospital discharge data or the underlying cause of 
death from national mortality statistics. The International 
Classification of Diseases (ICD) codes (versions 9 and/or 
10) were used to define outcome variables. New Zealand 
hospitals used an Australian modification of the ICD-10 
classification called ICD10-AM.26
CVD in both cohorts included the following conditions: 
CHD; HF; cerebrovascular disease including TIA; diseases 
of arteries, arterioles and capillaries including atheroscle-
rosis, aneurysm and dissection as well as embolism and 
thrombosis. For the Norwegian cohort, this included 
the codes: ICD9: 410–414, 428, 430–438, 440, 441 except 
441.7, 442, 443.9, 444; ICD10: I20–I25, I50, I60–I69, I70–
I79, G45. The CVD variable in the New Zealand PREDICT 
cohort included the same ICD10 codes as just listed, and 
also some additional ICD10-codes (I469, J81, G460–
G468, Z951, Z955, Z958, Z959) plus a list of procedure 
codes (too many to be listed here). The PREDICT-CVD 
outcome has been described elsewhere.19
ethnicity
Ethnicity in the New Zealand PREDICT data was based 
on two sources: (1) the PREDICT template filled in by 
the GP and (2) the National Health Index dataset, both 
according to pre-defined categories. A prioritising algo-
rithm was used to agree on one ethnicity in case of multiple 
ethnicities recorded (details can be found in the online 
supplementary file entitled the VIEW Ethnicity Protocol). 
The system for coding ethnicity in New Zealand enables 
identification of Indian people, who account for approxi-
mately 90% of South Asian people living in New Zealand. 
The remaining South Asian ethnic groups are classified as 
part of the ‘Other Asian’ ethnic group in national health 
data and so could not be included here. Indian people 
can include both immigrants and individuals who have 
been born in New Zealand with parents (or older gener-
ations) who have immigrated. The majority of this group 
are immigrants since 76.5% of the people who identified 
themselves with the Indian ethnic group in New Zealand 
in 2013 were born overseas.27
For the Norwegian cohort, we used country of birth 
merged into larger world regions to define ethnicity.28 
We defined South Asians as individuals who migrated to 
Norway from Bangladesh, Myanmar, Sri Lanka, Pakistan, 
India or Nepal.28 The largest share of South Asians in this 
dataset (95%) came from the HUBRO or the I-HUBRO 
study. HUBRO and I-HUBRO combined included 1145 
Sri Lankans and 780 Pakistanis,29 indicating that about 
50% of the South Asian group (n=2206) in the present 
study are Sri Lankans and 35% are Pakistanis.
In general, we refer to the ethnic groups as South 
Asians (South Asians in Norway and/or Indians in New 
Zealand) and Europeans (ethnic Norwegians and/or 
New Zealanders with ethnic European origin). Most Euro-
pean New Zealanders are of British and Irish ancestry, of 
whom about three-quarters were born in New Zealand.
statistical analysis
Baseline characteristics are reported as mean values with 
SD for continuous variables and fractions for categorical 
variables. We tested the differences between the ethnic 
groups adjusted for age by analysis of covariance. We 
used Cox regression models to examine the prospective 
relationship between baseline risk factors (BP, lipids, 
diabetes and smoking) and time until subsequent first 
CVD event. People were censored if they died from other 
causes (n=961 in PREDICT and n=276 in CONOR). 
Cox regression was also used to calculate HRs for CVD 
in South Asians versus Europeans using ethnicity as the 
exposure variable and adjusting for risk factors. The 
order we added the risk factors to the model was based 
on the distribution of risk factors in the subpopulations. 
This meant that we first introduced the risk factors that 
were more prevalent among South Asians compared 
with Europeans (diabetes and TC/HDL ratio) and 
then added the two less prevalent risk factors (SBP and 
smoking). Additional analyses where we added the risk 
factors in different orders and looked at each risk factor 
in separate models with only age as covariate did not 
change the conclusions (Tables A1 and A2 in the online 
supplementary appendix). Proportional hazards assump-
tions were tested using scaled Schoenfeld residuals.30 All 
analyses were stratified by sex and ethnicity, except for 
the analyses where ethnicity was the exposure variable in 
which we only stratified by sex. Only complete cases were 
included in the analyses. Stata V.14 was used for analyses 
in the Norwegian data and Stata V.11 for analysis in the 
New Zealand data.
To check whether the use of BP medication at baseline 
would impact the analyses where SBP were included, we 
repeated the Cox regression analyses excluding people 
using antihypertensive medication at baseline. Corre-
spondingly, we also repeated the Cox regression analyses 
for TC/HDL ratio without people using lipid-lowering 
medication at baseline. In addition, since excluding those 
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at highest risk could potentially impact the sensitivity 
analyses, we also adjusted for medication use without 
excluding anyone from the analyses (Tables A3and A4 in 
the online supplementary appendix).
ethics
The current project was approved by the Regional 
Committee for Medical Research Ethics, Health Region 
West. The PREDICT study was approved by the Northern 
Region Ethics Committee Y in 2003 (AKY/03/12/134), 
and later annually approved by the National Multi Region 
Ethics Committee since 2007 (MEC07/19/EXP).19 Each 
individual CONOR study was approved by the Norwe-
gian Data Inspectorate and evaluated by the Regional 




The final study sample from the New Zealand cohort 
consisted of 129 449 individuals (43% women) of Euro-
pean (87%) or Indian ethnicity (13%) with no history 
of CVD, atrial fibrillation or renal disease. Correspond-
ingly for the Norwegian cohort, the final study sample 
consisted of 16 606 individuals (54% women) born in 
either Norway (87%) or South Asia (13%) with no history 
of CVD or atrial fibrillation.
At baseline, the Norwegian cohort was younger than 
the New Zealand cohort, and New Zealand women were 
older than New Zealand men (table 1). In both cohorts, 
South Asians were younger than Europeans.
South Asians had lower levels of TC and HDL and 
higher mean levels of TC/HDL ratios than Europeans in 
both Norway and New Zealand. South Asians also had the 
lowest SBP levels (table 1). These differences persisted 
after adjustment for age (P<0.05 for differences between 
ethnic groups—results not shown).
The diabetes baseline prevalence was higher among 
South Asians compared with Europeans in both cohorts 
(table 1). The difference in diabetes were the same after 
adjustment for age (P<0.001). Antihypertensive and 
lipid-lowering treatments were generally more prevalent 
among South Asians than Europeans, and more prevalent 
in the New Zealand cohort compared with the Norwegian 
cohort. Cigarette smoking was more common among 
Europeans than South Asians, and practically none of the 
South Asian women smoked. Mean follow-up time was 
significantly longer in the Norwegian cohort than in the 
New Zealand cohort (table 1).
cVd events
During follow-up, we observed 2654 CVD events among 
129 449 individuals in the New Zealand cohort (378 874 
person-years) and 743 new CVD events among the 16 606 
individuals in the Norwegian cohort (139 470 person-
years). The overall crude rates were 700 per 100 000 
person-years in the New Zealand cohort and 533 per 100 
000 person-years in the Norwegian cohort. Ethnic specific 
rates for men and women in the two cohorts are shown 
in table 2 and in Tables A5–A8 of the online supplemen-
tary appendix. Also crude rates and age-adjusted HRs of 
CVD by risk factors, ethnic groups, cohort and gender 
can be found in the same tables (online supplementary 
appendix).
Prospective associations between risk factors and cVd
Increasing age was significantly associated with risk of 
CVD in both ethnic groups in both cohorts (table 2). 
The age effect was very similar within the countries for 
both ethnic groups and gender, but was stronger in the 
Norwegian cohort compared with the New Zealand 
cohort. After adjustment for age, the traditional CVD 
risk factors were positively associated with CVD in both 
ethnic groups, across gender and country. Whereas all 
the risk factor–CVD event associations were statistically 
significant in Europeans, the 95% CIs were wider and 
the results not always statistically significant among South 
Asians. The relationship between SBP, TC/HDL ratio, 
smoking and subsequent CVD appeared to be weaker in 
Indian men compared with European men in the New 
Zealand cohort. The prospective association between the 
risk factors and CVD changed little after adjusting for the 
other risk factors in addition to age (results not shown). 
In the sensitivity analyses where we either adjusted for 
medication use (Table A3 in the Appendices) or excluded 
people using BP- and lipid lowering medication at base-
line (results not shown), the estimates for the prospective 
associations between risk factors and CVD were similar 
as in the main analyses. However, for women in the New 
Zealand cohort, after excluding people on lipid-lowering 
medication, the HR for TC/HDL ratio changed to 1.12 
(95% CI 0.91 to 1.39) for Indian women and to 1.20 
(95% CI 1.12 to 1.27) for European women.
ethnic difference in cVd
South Asians of both genders in Norway and New Zealand 
had increased risk of CVD compared with the European 
majority populations (table 3), with age-adjusted HRs 
ranging from 1.42 to 1.92. After adjustment for TC/HDL 
ratio and diabetes, the HRs for South Asians versus Euro-
peans were reduced and no longer significant in women. 
Additional adjustments for SBP and smoking increased 
the HRs again so that South Asians in both countries 
had significantly increased risk of CVD compared with 
Europeans. After adjustment for age, TC/HDL ratio, 
diabetes, SBP and smoking, the HRs for the excess risk in 
South Asians compared with Europeans varied from 1.39 
to 1.76. The largest reduction in risk estimate after full 
adjustment was seen in South Asian men in the Norwe-
gian cohort where the HR was lowered by approximately 
38% after adjusting for the four major risk factors. The 
smallest reduction in risk estimate after adjustment was 
among South Asian women in the New Zealand cohort 
where the risk estimate was only reduced by 7% (from 
1.42 to 1.39).
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Table 1 Baseline characteristics (unadjusted) of the Norwegian and New Zealand participants. Participants free of prior CVD.
Men Women
European Indian European Indian
New Zealand cohort
N 63 319 9997 49 094 7039
Age (years) 55.0 (9.3) 47.4 (9.7) 58.7 (8.7) 52.9 (8.5)
Age range 30.0–74.0 30.0–74.0 30.0–74.0 30.0–74.0
TC (mmol/L) 5.36 (1.1) 5.09 (1.1) 5.68 (1.1) 5.04 (1.0)
HDL cholesterol (mmol/L 1.29 (0.4) 1.14 (0.3) 1.59 (0.5) 1.30 (0.3)
LDL cholesterol (mmol/L) 3.3 (1.0) 2.9 (1.0) 3.4 (1.1) 2.8 (0.9)
TC/HDL ratio 4.35 (1.3) 4.60 (1.3) 3.68 (1.1) 3.93 (1.1)
SBP (mm Hg) 131.5 (16.3) 125.3 (16.1) 131.6 (17.4) 126.1 (17.4)
Diastolic blood pressure 
(mm Hg)
80.5 (10.0) 79.1 (10.4) 78.8 (9.7) 77.4 (9.8)
Hypertension* (%) 40 34 44 39
Type 2 diabetes† (%) 9 24 9 29
Former smokers (%) 19 6 16 1
Current smokers (%) 12 9 10 1
Family history of CVD‡ (%) 12 8 15 10
Antihypertensive treatment 
(%)
24 26 30 32
Lipid-lowering treatment (%) 18 27 18 27
Follow-up time (years) 2.94 (2.3) 2.93 (2.0) 2.92 (2.3) 2.83 (1.9)
Men Women
Norwegian South Asian Norwegian South Asian
Norwegian cohort
N 6385 1 239 8015 967
Age (years) 43.7 (11.2) 41.4 (7.8) 43.9 (10.9) 40.3 (7.9)
Age range 30.0–70.1 30.0–67.8 30.0–74.9 30.0–65.5
TC (mmol/L) 5.60 (1.1) 5.48 (1.0) 5.41 (1.0) 4.98 (0.9)
HDL cholesterol (mmol/L 1.31 (0.3) 1.07 (0.2) 1.62 (0.4) 1.24 (0.3)
TC/HDL ratio 4.55 (1.4) 5.33 (1.4) 3.52 (1.1) 4.22 (1.2)
SBP (mm Hg) 132.6 (14.4) 126.6 (13.2) 124.0 (15.7) 119.1 (15.6)
Diastolic blood pressure 
(mm Hg)
77.6 (10.8) 76.9 (9.8) 71.5 (10.3) 70.0 (10.1)
Hypertension* (%) 30 22 19 16
Diabetes (%) 1.6 8.6 1.4 10.9
Former smokers (%) 28 16 26 2
Current smokers (%) 26 25 31 1
Family history of heart 
disease§ (%)
33 24 37 27
Family history of stroke¶ (%) 11 3 13 4
Antihypertensive treatment 
(%)
6 8 6 9
Lipid-lowering treatment (%) 4 6 3 6
Follow-up time (years) 8.44 (1.4) 7.65 (1.4) 8.54 (1.2) 7.88 (1.1)
*Hypertension is defined as having SBP ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or using blood pressure medication.
†The diabetes variable in the New Zealand data includes people with diabetes of unknown type (5%) and type 2 diabetes (95%), while in the 
Norwegian data we could not differentiate between different types of diabetes.
‡Family history of CVD in the New Zealand data: self-reported familial history of ischaemic heart disease or ischaemic stroke occurring in a father or 
brother aged <55 years, or a mother or sister aged <65 years.
§Parents or siblings have had heart attack or angina pectoris (self-report).
¶Parents or siblings have had stroke (self-report).
Data are mean values (SD) for continuous variables and prevalence (%) for categorical variables.
CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure, TC, total cholesterol.
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N events/N 1791/73 308 436/7387 863/56 126 264/8558
Adjusted for
Age 1.75 (1.53 to 2.00) 1.92 (1.48 to 2.49) 1.42 (1.16 to 1.75) 1.87 (1.21 to 2.87)
Age, TC/HDL ratio 1.77 (1.55 to 2.02) 1.66 (1.27 to 2.16) 1.41 (1.14 to 1.73) 1.52 (0.98 to 2.36)
Age, TC/HDL ratio, diabetes 1.49 (1.30 to 1.71) 1.42 (1.08 to 1.87) 1.15 (0.92 to 1.42) 1.30 (0.82 to 2.04)
Age, TC/HDL ratio, diabetes, SBP 1.57 (1.37 to 1.80) 1.53 (1.16 to 2.01) 1.19 (0.96 to 1.47) 1.31 (0.83 to 2.07)
Age, TC/HDL ratio, diabetes, SBP, smoking 1.64 (1.43 to 1.88) 1.57 (1.19 to 2.07) 1.39 (1.11 to 1.73) 1.76 (1.09 to 2.82)
All had complete information on the risk factors.
CVD, cardiovascular disease; HDL, high-density lipoprotein; NZ, New Zealand; SBP, systolic blood pressure; TC, Total cholesterol.
Additional analyses showed that the excess risk in South 
Asians was particularly high for CHD. The full-adjusted 
HRs for CHD (corresponding to the analyses in the last 
row of table 3) were 2.07 (95% CI 1.76 to 2.44) in South 
Asian men and 1.60 (95% CI 1.20 to 2.13) in South Asian 
women in New Zealand. In the Norwegian cohort, the 
full-adjusted HRs for CHD were 1.86 (95% CI 1.36 to 
2.55) in South Asian men and 2.84 (95% CI 1.61 to 5.03) 
in South Asian women (Table A9 in the Appendices). 
In the sensitivity analyses for table 3 where we excluded 
people using BP-lowering or lipid-lowering medication at 
baseline (results not shown) or adjusted for BP-lowering 
or lipid-lowering medication (Table A4 in the Appen-
dices), the patterns according to the risk factor adjust-
ments remained the same as in the main analysis.
dIscussIOn
This study confirmed that the traditional risk factors SBP, 
TC/HDL ratio, diabetes and smoking are all positively 
associated with risk of CVD in South Asians as well as in 
Europeans. The present study also confirmed that South 
Asians had an increased risk of CVD compared with Euro-
peans and that ethnic differences in the distribution of 
TC/HDL ratio and type 2 diabetes appear to explain 
some of this excess risk.
The main strengths of this study are the prospective 
study design, and inclusion of data from two countries. 
Unfortunately, we lacked information about duration of 
stay for the immigrants, and the ethnic groups that we 
studied are heterogeneous.
Strengths of the PREDICT cohort are the large sample 
size and the completeness of risk factors included in 
the risk-assessment. Only 0.01% were missing on any 
of the four major risk factors because they were part of 
the prediction algorithm and thereby compulsory to 
fill in to the PREDICT template. Furthermore, compre-
hensive national health registers were used to identify 
and exclude people with prior CVD and to determine 
cardiovascular outcomes. In the New Zealand cohort, 
some recruitment bias is likely since risk assessment was 
initially prioritised for high-risk patients. Indian patients 
are therefore over-represented in the cohort together 
with Maoris and Pacifics.19 The representativeness of the 
source population is, however, improving as PREDICTs 
coverage increases. In this study, follow-up extended to 
2012 when PREDICT included 50% of guideline-eligible 
patients in the practices where the PREDICT software is 
used.19 We did not assume that the cohorts were repre-
sentative of the general populations in the two countries, 
but that the ethnic groups within the two cohorts should 
be comparable. Adjusting for age was therefore particu-
larly important in the New Zealand cohort since South 
Asians were around 7 years younger than Europeans. 
Results from the two cohorts showed approximately the 
same regarding ethnic differences, which is a strength 
concerning the external validity of these results. A limita-
tion in the New Zealand data is short follow-up time 
restricting the statistical power. Another limitation is the 
lack of standardised BP measurements since recorded BP 
can easily be affected by a range of factors including the 
type of device used.32
Strengths of CONOR data are the standardised 
measurements of risk factors, the linkage with disease 
outcomes from comprehensive national health registers 
and the standardised way of defining ethnicity using 
country of birth. A validation study examining the Oslo 
Health study, showed that participants with a non-Western 
background had a lower participation rate than others.33 
This may reflect self-selection, which can work both 
ways; healthy and resourceful people have the energy 
and motivation to participate or less healthy people who 
think their health could benefit from participating do so. 
Self-selection is unlikely to influence associations between 
risk factors and subsequent disease, but could influence 
the ethnic comparisons if the mechanisms were system-
atically different for the ethnic groups. The South Asian 
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group in the Norwegian cohort was relatively small, which 
reduced the precision of the estimates and limited the 
statistical power. Another limitation in the CONOR data 
is missing information on some of the risk factors (see 
Tables A5-A8 in the Appendices for numbers of missing). 
However, the extent of missing was small. The risk factor 
with most missing in CONOR was diabetes (3% for the 
total cohort).
In both cohorts, the endpoints are based on register 
data, including both hospital and mortality data, which 
enables almost complete ascertainment of CVD events. In 
New Zealand, more than 95% of patients with an acute 
CVD event are managed by government-funded health 
services.19 However, CVD events occurring among partic-
ipants who travelled outside of New Zealand, those who 
emigrated after the index CVD risk assessment or among 
participants treated in private hospitals would not be 
captured in the national hospital and mortality registers.19 
We have no information about possible emigration for 
the New Zealand cohort, but for the Norwegian cohort 
we know that few people have emigrated (about 1% of 
the ethnic Norwegians and <3% of the South Asians who 
participated in the Oslo health studies had emigrated by 
the end of follow-up). A limitation for both cohorts is also 
the lack of medication data during follow-up. However, 
adjustment for baseline medication did not change the 
estimates (Tables A3-A4 in the Appendices), and table 1 
shows that South Asians used more antihypertensives and 
lipid-lowering drugs at baseline than Europeans. Both 
countries have universal healthcare and South Asians 
should have the same access to cardiovascular medication 
as Europeans. It is therefore not likely that lack of treat-
ment explains the differences in risk of CVD between the 
two ethnic groups.
Our finding that the traditional major CVD risk factors 
contribute to the development of CVD in South Asians 
as in Europeans was an expected, yet important, finding 
since most knowledge about CVD prevention is based on 
studies in populations of European descent, and some 
have questioned whether these risk factors apply world-
wide.11 34 This finding is in line with the large INTER-
HEART and INTERSTROKE case–control studies,11 12 
which reported that 90% of the population attributable 
risk for AMI and stroke worldwide was accounted for by, 
respectively, nine and ten (similar) risk factors, including 
those included in the present study. We are only aware 
of two other prospective studies reporting HRs for the 
prospective relationship between major CVD risk factors 
and subsequent CVD in South Asians.7 35 One of these 
studies included only men,7 and the other showed esti-
mates for men and women combined and did not include 
blood lipids.35 These studies generally agree with our 
findings that traditional risk factors contribute to the 
development of CVD in South Asians as in Europeans.7 35 
Also, consistent with previous reports,5 6 we found that 
South Asians in both Norway and New Zealand have a 
higher risk of CVD compared with the European majority 
populations. By including all the measured risk factors 
(BP, TC/HDL ratio, diabetes and smoking) as adjustment 
variables in one statistical model, we could not explain 
the higher risk of CVD in South Asians. However, the 
increased risk was attenuated when we only included the 
risk factors more prevalent in South Asians than in Euro-
peans (TC/HDL ratio and diabetes).
The excess risk of CVD among South Asians compared 
with Europeans in the Norwegian cohort was almost 
two-fold. This is comparable to what we reported previ-
ously when studying the total Norwegian population.5 
The South Asians in the New Zealand cohort had 
42%–75% higher risk of CVD compared with Euro-
pean New Zealanders, which also agrees with previous 
New Zealand studies.6 In both the Norwegian and New 
Zealand data, South Asians had higher baseline levels 
of dyslipidaemia indicated by the TC/HDL ratio and 
higher diabetes prevalence compared with the European 
majority populations, which is in general agreement with 
previous knowledge from these countries.14–16 Attenua-
tion of the excess risk in South Asians versus Europeans 
was best achieved in the Cox model only including 
diabetes and TC/HDL ratio as covariates in addition to 
age. The same was found in both cohorts, clearly indi-
cating that the unfavourable distribution of blood lipids 
and type 2 diabetes explains some of the higher risk of 
CVD in South Asians. South Asians generally have a high 
prevalence of metabolic risk factors related to insulin 
resistance, often clustered so that they match the concept 
of the metabolic syndrome.36–39 A British cohort study 
that tested whether traditional risk factors could account 
for the high mortality of CHD among South Asian men 
compared with European men, reported that adjusting 
for insulin resistance, dyslipidaemia and hyperglycaemia 
in South Asians did not explain their higher risk.7 
However, they also adjusted for smoking and TC, which 
were both less prevalent/lower among South Asian men 
compared with European men.
It is unclear why the traditional risk factors do not 
completely explain the excess risk of CVD in South 
Asians. This could be related to incomplete adjustments; 
due to either imprecise measurement of risk factors or 
that other important risk factors were not included (eg, 
waist measurement, length of time since diabetes diag-
nosis). A number of non-conventional risk factors are 
also thought to partially account for the high risk of CVD 
in South Asians, including dysfunctional HDL, C reactive 
protein, thrombogenic risk factors, telomere length, high 
homocysteine levels and low birth weight.40 41 Socioeco-
nomic factors could probably also explain some of the 
differences in risk between the ethnic groups, but we 
did not have such variables. Another possibility is that 
risk factors work cumulatively over time in the develop-
ment of atherosclerosis, and some risk factors may also 
work at specific and crucial time points during the life 
course. Measurements taken on single occasions may also 
lead to an underestimation of the strength between the 
usual levels of the risk factors and later disease, known as 
the regression dilution bias.42 Consequently, it is unlikely 
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that the ethnic differences would disappear completely 
by adjusting for selected risk factors measured once in 
midlife.
Although South Asians seem to have an underlying 
susceptibility for metabolic diseases, traditional and modi-
fiable risk factors are important for preventing disease. 
Our analyses indicate that it is important to focus on the 
prevention of type 2 diabetes and dyslipidaemia when 
aiming to reduce the burden of CVD among South Asians. 
The additional effect of abdominal obesity for the risk of 
CVD among South Asians in Norway and New Zealand 
has, however, not yet been studied although we know 
that the prevalence is high in this ethnic group.37 43 In 
both Norway44 45 and New Zealand,46 intervention studies 
targeting immigrants from South Asia have been carried 
out with some promising results. A UK study that 
prospectively examined the influence from four health 
behaviours on the risk of CVD in South Asian immigrants 
and UK Europeans found an important potential for 
disease prevention among South Asians if they adhered 
to healthy behaviours.8
cOnclusIOn
Ethnic differences in distribution of TC/HDL ratio and 
type 2 diabetes explained some, but not all, of the excess 
risks of CVD in South Asians compared with Europeans 
in Norway and New Zealand. Smoking and elevated BP 
were less prevalent among South Asians and thus could 
not explain any of the observed differences in risk of 
CVD. Targeted diabetes and dyslipidaemia management 
among South Asians, including support for healthy life-
style choices, should be a priority if the high burden of 
CVD in these ethnic populations is to be reduced.
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